logo-loader
IXICO PLC

IXICO plc - Contract win and contract extension

RNS Number : 1444F
IXICO plc
21 May 2026
 

IXICO plc

("IXICO", the "Company" or the "Group")

 

Alzheimer's contract win and Phase 2 clinical trial contract extension with total value of £1.3 million

 

 

21 May 2026, IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug and diagnostics development in neurological disorders, today announced a contract win and contract extension with a total value of £1.3 million over 2 years.

 

Blood based biomarker validation contract

IXICO will provide amyloid PET imaging analytics to validate a new Alzheimer's Disease (AD) blood-based biomarker test for a global diagnostics and life sciences company with the aim of facilitating FDA regulatory clearance. 

 

Phase 2 contract extension

This extends an existing Phase 2 Huntington's Disease (HD) clinical trial contract with a leading global pharmaceutical company, expanding the existing analysis methodologies with three additional analysis approaches.

 

Bram Goorden, Chief Executive Officer of IXICO, commented: "These latest contract wins are first and foremost important for progress in research and patient care. They also fit squarely in the growth strategy for our company, hitting three key components of the plan: deepening impact in broader CNS areas such as AD while maintaining leadership in rare neurodegenerative disease areas like HD, enabling novel modalities and moving toward high-value later stage clinical development work. It is deeply satisfying to see an increasing number of clients recognise IXICO's leading role in the field of CNS precision medicine".

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the UK version of the EU Market Abuse Regulation 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended and supplemented from time to time. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

Ends

 

For further information please contact:

 

IXICO plc

+44 (0) 20 3763 7499

Grant Nash, Chief Financial Officer

James Chandler, Chief Business Officer


 

Cavendish Capital Markets Limited

(Nominated Adviser and Sole Broker)

 

+44 (0) 20 7220 0500

Giles Balleny, Isaac Hooper (Corporate Finance)

Nigel Birks (Healthcare Specialist Sales)

Harriet Ward (Corporate Broking)

Michael F Johnson (Sales)


 

 

About IXICO www.IXICO.com

IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring.   As a key part of the global neurological disease research community, the Company has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) working with leading pharma companies, innovative biotech's, disease consortia and non-profit organisations. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands scans and built an expansive network of expert imaging centres around the world.  

 

The IXICO Platform is tailor-made for neurological disease, reliably processing data from global trials, precisely measuring key imaging biomarkers associated with the identification, progression and treatment of diseases such as Alzheimer's, Huntington's and Parkinson's.  Image data is interrogated by the Platform and IXICO's expert scientists translating complex data into clinically meaningful while minimizing data variability and increasing reproducibility.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
CNTXBLFLQELZBBZ
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

IXICO CTO on IXI platform upgrade, AI and expanding technology partnerships

IXICO PLC (LSE:IXI, OTC:PHYOF) chief technology officer Mark Austin talked with Proactive's Stephen Gunnion about the latest upgrade to its IXI platform, expanding technology partnerships and the growing role of artificial intelligence (AI) in neurological drug development. Austin explained...

7 hours, 54 minutes ago

4 min read